Aspirin or P2Y12i monotherapy for secondary prevention in patients with CAD?
This video was recorded during the ESC Congress 2022 in Barcelona, Spain.
Marco Valgimigli, MD, PhD - Cardiocentro Ticino Foundation, Lugano in Switzerland.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: